Wed 25 November 2020:
Developers of Russia’s Sputnik V coronavirus vaccine said on Tuesday, that Sputnik V is 95 percent effective according to a second interim analysis of clinical trial data,
The calculations were based on preliminary data obtained 42 days after the first dose, Russia’s health ministry, the state-run Gamaleya research centre and the Russian Direct Investment Fund (RDIF) said in a statement.
Currently, Russia is holding Phase 3 of the Sputnik V vaccine trials, engaging 40,000 people, the statement added.
AFTER PARLIAMENTARY POLLS
DAY IN SUDAN’S DARFUR
FIRST BATCH OF RUSSIAN VACCINES
BEFORE JOE BIDEN INAUGURATION:
ACTING PENTAGON CHIEF
AS SCIENTISTS STUDY NEW VARIANT
YOU CAN ENHANCE CONCRETE WITH IT
BACKED FIGHTERS IN SYRIA’S HOMS
PROJECT TO START JAN 26
DESPITE OBJECTION FROM
ECONOMY GREW 2.3% IN 2020
WANTS 70% VACCINATION
RATE IN BLOC BY SUMMER
“As of November 24, no unexpected adverse complications were detected during the Sputnik V study. Some of the vaccinated patients experienced short-term malaises, such as pain at the injection site, flu-like syndrome, including fever, weakness, fatigue, and headache,” it said.
The data obtained during the trials will be published by the research team of the Gamaleya Research Institute of Epidemiology and Microbiology, which developed the vaccine, in one of the leading international medical issues.
At the end of the third phase of clinical trials, the institute will provide access to the full trial report, it said.
Russia became the first country in the world to register a coronavirus vaccine for use, named Gam-COVID-Vac (Gamaleya COVID Vaccine) by the developers and with the trade name Sputnik V — with V referring to the vaccine.
The vaccine is designed to be administered through two injections to prolong the immunity, and at the current stage it is authorized for people aged 18-60 and can be combined with other antigens, including against the flu.
FOLLOW INDEPENDENT PRESS:
TWITTER (CLICK HERE)
FACEBOOK (CLICK HERE)
Think your friends would be interested? Share this story!